In 1781 was created Takeda Pharmaceutical, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Osaka. The company was established in Asia in Japan.
This organization was formed by Chobei Takeda I.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline Outpost Medicine, BioNumerik Pharmaceuticals, Molecular Templates Among the most popular fund investment industries, there are Therapeutics, Health Care. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The fund is generally included in less than 2 deals every year. This Takeda Pharmaceutical works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2017. The high activity for fund was in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Takeda Pharmaceutical, startups are often financed by F-Prime Capital, New Enterprise Associates, Sante Ventures. The meaningful sponsors for the fund in investment in the same round are SMBC Venture Capital, Mitsubishi UFJ Capital, Wellington Management. In the next rounds fund is usually obtained by Takeda Ventures, Adams Street Partners, Logos Capital.
Related Funds
| Fund Name | Location |
| CGF Capital Management | Chaoyang, China, Liaoning |
| Chuo Shinkin Venture Capital | - |
| Consumer Growth Partners | New York, United States, White Plains |
| Dingsheng Xinhe | Beijing, China, Haidian |
| Elias Tabet | - |
| Guojun Ziben | China, Henan, Zhengzhou |
| Keppel Data Centres | Central, Central Region, Singapore |
| Leaguer Angel | China, Guangdong, Shenzhen |
| Shanghai Venture Capital Co.,Ltd | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ambys Medicines | $47M | 21 Dec 2021 | - | ||
Cardurion Pharmaceuticals | $300M | 27 Oct 2021 | Boston, Massachusetts, United States | ||
xFOREST Therapeutics | 06 Oct 2020 | Kyoto, Kyoto Prefecture, Japan | |||
GEXVal | $3M | 17 Jul 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Reborna Biosciences | $2M | 25 Jun 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Fimecs | $2M | 01 Apr 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Chordia Therapeutics | $10M | 23 Nov 2017 | Fujisawa, Kanagawa Prefecture, Japan | ||
Cerevance | $5M | 03 May 2017 | Cambridge, Massachusetts, United States | ||
Avidity Biosciences | $16M | 05 Jan 2017 | San Diego, California, United States |
– Seattle’s Presage Biosciences announced $13m in funding.
– The funding was led by Arch Venture Partners and joined by existing investors, including Takeda Pharmaceutical, Celgene and Bristol Myers Squibb (BMS).
– The company has raised a total of $35m in equity.
– Presage is a biotech device company that has built a platform for testing new cancer drugs used to treat tumors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ambys Medicines | $47M | 21 Dec 2021 | - | ||
Cardurion Pharmaceuticals | $300M | 27 Oct 2021 | Boston, Massachusetts, United States | ||
xFOREST Therapeutics | 06 Oct 2020 | Kyoto, Kyoto Prefecture, Japan | |||
GEXVal | $3M | 17 Jul 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Reborna Biosciences | $2M | 25 Jun 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Fimecs | $2M | 01 Apr 2018 | Fujisawa, Kanagawa Prefecture, Japan | ||
Chordia Therapeutics | $10M | 23 Nov 2017 | Fujisawa, Kanagawa Prefecture, Japan | ||
Cerevance | $5M | 03 May 2017 | Cambridge, Massachusetts, United States | ||
Avidity Biosciences | $16M | 05 Jan 2017 | San Diego, California, United States |
